P Péran1, A S Salabert2, T Dondaine3, X Leclerc3, H Gros-Dagnac2, J-P Ranjeva4, R Lopes3, L Lanteaume4,5, O Blin4,5, C Thalamas6, R Bordet3, P Payoux2. 1. Toulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France. patrice.peran@inserm.fr. 2. Toulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France. 3. Degenerative & Vascular Cognitive Disorders Research Unit, INSERM-Lille University-Lille University Hospital, Lille, France. 4. Centre for Metabolic Exploration by Magnetic Resonance (CEMEREM), Aix-Marseille University-CNRS-CRMBM-Timone University Hospital, Marseille, France. 5. Department of Clinical Pharmacology (UPCET), Aix-Marseille University-INSERM-Timone University Hospital, Marseille, France. 6. Clinical Investigation Center (CIC1436), Toulouse, France.
Abstract
RATIONALE: Donepezil is a potent, noncompetitive, reversible, clinically effective acetylcholinesterase inhibitor. The effects of this drug on healthy brains have seldom been investigated. OBJECTIVES: The primary objective of the present study was to identify possible functional connectivity markers of the effect of donepezil in healthy young adult volunteers. METHODS: The study had a double-blind, randomized, crossover design. 30 healthy adult volunteers underwentresting-state MRI scans during 15 days of donepezil or placebo treatment, in accordance with the design. RESULTS: Results showed significant differences in intrinsic functional connectivity between donepezil and placebo, mainly in the right executive control network (RECN). More specifically, we found a decrease in the connectivity of the right inferior parietal node with other RECN nodes. Analysis using the cingulate cortex and parahippocampal regions as seeds also revealed complex modulation of functional connectivity in the donepezil condition. CONCLUSIONS: In conclusion, donepezil treatment for 15 days may result in reorganization of resting-state networks, compared with placebo.
RCT Entities:
RATIONALE: Donepezil is a potent, noncompetitive, reversible, clinically effective acetylcholinesterase inhibitor. The effects of this drug on healthy brains have seldom been investigated. OBJECTIVES: The primary objective of the present study was to identify possible functional connectivity markers of the effect of donepezil in healthy young adult volunteers. METHODS: The study had a double-blind, randomized, crossover design. 30 healthy adult volunteers underwent resting-state MRI scans during 15 days of donepezil or placebo treatment, in accordance with the design. RESULTS: Results showed significant differences in intrinsic functional connectivity between donepezil and placebo, mainly in the right executive control network (RECN). More specifically, we found a decrease in the connectivity of the right inferior parietal node with other RECN nodes. Analysis using the cingulate cortex and parahippocampal regions as seeds also revealed complex modulation of functional connectivity in the donepezil condition. CONCLUSIONS: In conclusion, donepezil treatment for 15 days may result in reorganization of resting-state networks, compared with placebo.
Authors: Leigh J Beglinger; Brenda L Gaydos; David A Kareken; Oranee Tangphao-Daniels; Eric R Siemers; Richard C Mohs Journal: J Psychopharmacol Date: 2004-03 Impact factor: 4.153
Authors: David B FitzGerald; Gregory P Crucian; Jeannine B Mielke; Brian V Shenal; David Burks; Kyle B Womack; Georges Ghacibeh; Valeria Drago; Paul S Foster; Edward Valenstein; Kenneth M Heilman Journal: Cogn Behav Neurol Date: 2008-06 Impact factor: 1.600
Authors: Joseph S Goveas; Chunming Xie; B Douglas Ward; Zhilin Wu; Wenjun Li; Malgorzata Franczak; Jennifer L Jones; Piero G Antuono; Shi-Jiang Li Journal: J Magn Reson Imaging Date: 2011-07-18 Impact factor: 4.813
Authors: Rasmus M Birn; Erin K Molloy; Rémi Patriat; Taurean Parker; Timothy B Meier; Gregory R Kirk; Veena A Nair; M Elizabeth Meyerand; Vivek Prabhakaran Journal: Neuroimage Date: 2013-06-06 Impact factor: 6.556
Authors: Gwenaëlle Douaud; Stephen Smith; Mark Jenkinson; Timothy Behrens; Heidi Johansen-Berg; John Vickers; Susan James; Natalie Voets; Kate Watkins; Paul M Matthews; Anthony James Journal: Brain Date: 2007-08-13 Impact factor: 13.501